KKR completed the acquisition of a majority stake in a biopharma royalty acquisition company, HCRx.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
KKR completed the acquisition of a majority stake in a biopharma royalty acquisition company, HCRx.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Kohlberg Kravis Roberts
American private equity fund manager
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
- Trump tariffs and onshoring benefit AI stocks, leading to automation and robotics support agreements involving Amazon and Richtech Robotics.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
Coverage
Newest first; wire copies grouped- Insider MonkeyKKR Acquires Majority Stake in HealthCare Royalty Partners KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it ha